Efforts to treat CF caused by the ΔF508 mutation focus on finding small molecular correctors that enhance ΔF508 CFTR folding co- and/or post-translationally and potentiators to improve its function (Fig 1A) [5, 6]. Here, CFTR is linked to cystic fibrosis.